EQT is a global private equity and infrastructure firm founded in 1994, headquartered in Stockholm, Sweden. It specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies with strong growth potential. EQT invests across various sectors, including healthcare, technology, services, industrials, and real estate, with a particular emphasis on Northern and Eastern Europe, Asia, and the US. The firm seeks to unlock growth potential in its portfolio companies, positioning them as sustainable market leaders, and typically holds investments for four to eight years. EQT also prioritizes ESG and impact investments in its infrastructure portfolio.
Unit 1507-1508 CITIC Square 1168, Nanjing Road West, Shanghai 200041, China
Sofia Ahuja
Partner
Christian Shin Høegh Andersen
Managing Director, Private Equity and Investment Advisory Professional
James Arrol
Managing Director, Fund Management
Teruyuki Asaoka
Managing Director
Fouad Azzam
General Partner
Fredrik Backman
Managing Director, Client Relations
Peter Balslev
Managing Director
Johann-Christoph Balzer
Partner, EQT Value-Add Infrastructure
Eirik Benzon
Managing Director, BPEA EQT Team
William Bergström
Director
Lennart Blecher
Deputy Managing Partner
Clemens van Blitterswijk
Founder of LSP Health Economics Fund
Mark Braganza
Partner, Investment Advisory
Carolina Brochado
Partner
Marc Brown JD
Partner and Head of EQT Growth
Anna Brundtland
Managing Director
Kenneth Cheong
Partner
Wonho Choi
Vice President
Henry Connon
Associate, Private Equity and Investment Advisory Professional
Crosby Cook
Partner, Infrastructure and Investment Advisory Professional
Guy Cui
Partner
Nicholas Curwen
Managing Director
Alex Darden
Partner, President and Head of EQT Infrastructure Advisory Team Americas
Rudy Dekeyser
Co-Founder Managing Director
Johan Dettel
Partner
Christina Drews
COO and Executive Committee
Asis Echaniz
Partner and Head of Spain
Andreas Eichelberger
Director
Frederik Elwing
Managing Director
Victor Englesson
Partner
Stephen Escudier
Partner
Ali Farahani
Partner
Frank Feng
Managing Director
Andreas Fischer
Partner
Mark Fogle
Partner and Head of EQT Exeter APAC
David Forde
Partner
Juho Frilander
Managing Director
Florian Funk
Partner, Private Equity
Guillermo Garcia-Barrero
Managing Director
Henrik Giver
Managing Director
Simon Gold
Managing Director, Client Relations and Capital Raising
Wolfgang Gorny
Partner, Private Equity
Alexander Greenbaum
Partner, Active Core Infrastructure Advisory Team and Investment Advisory Professional
Fabian Grone
Partner, Head of Asia
Floris van Halder
Managing Director
Sean Ham
Partner and Head of Asia Pacific
Frank Heckes
Partner, Private Equity
Erika Henriksson
Partner, Private Equity
Jak Hestnes
Managing Director and Board Member
Gerran Ho
Managing Director, Mid Market Asia
Christian Horn
Managing Director
Andreas Huber
Partner
Sara Huda
Managing Director and Head of Investment Services
Johan Hylander
Managing Director
Patrick Jaslowitzer
Managing Director
Neha Jatar
Managing Director
Yan Jiao
Partner
Herman Johre
Associate
Maarten de Jong
Partner, EQT Private Equity
Lars Jörnow
Partner
Kosmo Kalliarekos
Partner
Viviana Kane
Managing Director
Masahiko Kato
Managing Director and Head of Infrastructure Japan
Matthew Kestenbaum
Managing Director
Nils Ketter
Partner
Paul Kim
Managing Director
Kasper Grundtvig Knokgaard
Partner
Gleb Kozyritskiy
Managing Director
Elias Källström
Managing Director
Ulrich Kollensperger
Partner
Tobias Kung
Managing Director, Infrastructure
Priscilla Lam
Managing Director, Portfolio Monitoring
Lance Lan
Managing Director, Exit Management
Adam Larsson
Managing Director
Kenneth Lau
Associate
Edward Lavish
Managing Director, Portfolio Risk and Transactions
Eu Han Lee
Partner, Debt Capital Markets
Alex Lee
Partner
Hong Yong Leong
Partner
Janice Leow
Partner
William Liang
Director of European Firm
Benjamin Lim
Director
William Lindström
Managing Director
Gebhard Littich
Managing Director
Nicholas Macksey
Partner
Robert Maclean
Partner
Madeleine Magnerius
Director
Paola Maleh
Partner and Head of EMEA
Francesco Malvezzi
Managing Director, Infrastructure
Tadashi Maruoka
Partner
Axel Masucci
Managing Director
Arnav Mitra
Director
Mikael Moll
Managing Director, Public Value
Joep Muijrers
General Partner
Pascal Noel
Managing Director
Tetsuro Onitsuka
Partner and Head of Private Equity Japan
Alex Paganini
Associate, Infrastructure
Isabel De Paoli
Partner, Healthcare
Sydney Pardey
Managing Director
Tyler Parker
Managing Director
Daniel Perez
Partner
Christopher Popp
Managing Director
Shane Predeek
Partner
Vai Rajan
Head of EMEA Private Wealth Capital Raising and Director - Client Relations and Capital Raising
Thomas Rajzbaum
Managing Director and Partner, EQT Infrastructure
Hermann Rauch
Managing Director
Vera Rebanova
Partner, Client Relations and Capital Raising
Matthias Riefer
Managing Director, Private Equity
Niklas Ringby
Partner
Patrick Rodden
Managing Director and Head of Infrastructure for Australia and New Zealand
Maxwell Roitstein
Associate
Joakim Rubin
Partner
Isidoor Rutten
Partner and Head of Private Equity Benelux
Rob Ryan
Managing Director, Market Risk
Darlene Sammon
Partner
Carlos Santana
Partner, Private Equity
Anthony Santospirito
Partner
Mika Saukkonen
Managing Director, Infrastructure
Matthew Scattarella
Partner
Brendan Scollans
Partner
Nirav Shah
Partner, EQT Value-Add Infrastructure
Hemant Sharma
Managing Director
Piyush Singhvi
Managing Director, Infrastructure
Carl Sjölund
Partner, Infrastructure
Jared Small
Managing Director
Georg Stadler
Partner, Infrastructure
Dominik Stein
Partner and Head of EQT Growth Advisory Team
Joshua Stone
Managing Director, FO Head of Strategic Initiatives
Alexander Strassburger
Managing Director
Marc-Alexander Straubinger
Managing Director
Jan Stypulkowski
Managing Director
Sang Jun Suh
Partner
Anna Sundell
Partner, Infrastructure
Carl Svantesson
Partner
Miriam Tawil
Partner and Investment Advisory Professional
Michiel Thiessen
Managing Director
Elly Thio
Managing Director
Erwin Thompson
Partner, Infrastructure
Matteo Thun
Partner
Andrew Tirbeni
Managing Director, EQT Client Relations and Capital Raising
Wei Tor
Managing Director
Juan Vargas
Partner
Jan Vesely
Partner, Infrastructure
Marcus Wallinder
Partner and Deputy Head of Client Relations and Capital Raising
Forrest Wang
Managing Director, Private Equity
Ethan Waxman
Partner
Rickard Wilson
Managing Director
Matthias Wittkowski
Partner
Ken Wong
Partner and Head of Asia Pacific, Infrastructure
Philipp Worner
Director, Private Equity
Dayea Yeon
Managing Director and Head of Private Capital Korea
Shuting You
Managing Director
James Yu
Partner and Senior Bank Relationship Manager
Julia Zhu
Managing Director
Fredrik Atting
Partner
John Österlund
Managing Director
Zoe Zhu
Director
Past deals in DACH
Noema Pharma
Series B in 2024
Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address disabling symptoms in conditions affecting the nervous system, including Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma seeks to improve the quality of life and patient outcomes for individuals suffering from these rare conditions.
Sequana Medical
Post in 2024
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
FlixBus
Private Equity Round in 2024
FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.
Onward
Post in 2024
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Xeltis
Series D in 2023
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
IntegrityNext
Venture Round in 2023
IntegrityNext is a company based in Munich, Bayern, focused on providing a cloud-based platform for monitoring supplier sustainability and compliance. Established in April 2016 by Martin Berr-Sorokin, the platform allows businesses to automatically gather necessary supplier self-assessments and certifications while also monitoring social media for potential malpractice and reputational risks. Through its features, which include automated self-assessments, risk alerts, and a pre-built supplier questionnaire, IntegrityNext helps small and medium-sized enterprises navigate compliance data requirements set by international regulators. The platform's real-time dashboard and assessment framework enable companies to effectively manage compliance risks and streamline their processes.
Xeltis
Series D in 2023
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
va-Q-tec
Acquisition in 2023
va-Q-tec is a high-tech company established in 2001, specializing in innovative insulation solutions, particularly through vacuum insulation panels (VIPs). The company's products are designed to enhance energy efficiency and are environmentally friendly, making them suitable for various applications. va-Q-tec's technology significantly reduces energy costs in diverse sectors, including the transportation of pharmaceutical products, refrigeration and freezing appliances, construction, and automotive and aerospace industries. The company operates through several segments, with a strong presence in Germany and across the European Union. Its customer base spans multiple industries, including healthcare, logistics, appliances and food, construction, and technical sectors.
Cardiac Dimensions
Series D in 2023
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
SHL Medical
Secondary Market in 2022
SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.
Cardior Pharmaceuticals
Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.
Onward
Venture Round in 2021
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
Cardiac Dimensions
Series C in 2020
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
FoRx Therapeutics
Seed Round in 2020
FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company specializes in the development of innovative therapeutics for cancer treatment, specifically targeting key molecular pathways involved in DNA replication stress. By focusing on these novel pathways, FoRx Therapeutics aims to create first-in-class compounds that offer a new approach to targeted anticancer therapies. Through its research and development efforts, the company seeks to provide effective solutions in the fight against cancer.
Deutsche Glasfaser
Acquisition in 2020
Deutsche Glasfaser Holding GmbH, founded in 2012 and based in Borken, Germany, specializes in the planning, construction, and operation of fiber optic networks, particularly targeting rural and suburban areas. As a significant player in the broadband telecommunications sector, the company aims to facilitate nationwide fiber optic expansion, contributing to Germany's digital advancement. Deutsche Glasfaser focuses on delivering fast and cost-effective fiber-to-the-home (FTTH) connections in collaboration with municipalities, positioning itself as a leader in innovative planning and construction processes. With substantial backing from experienced investors, the company has established a strong financial foundation, making it one of the most robust providers in the German market.
SHL Medical
Private Equity Round in 2020
SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.
Atlantic Therapeutics Limited
Series B in 2019
Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.
SUSE
Acquisition in 2018
SUSE is a global leader in open source solutions, providing reliable and enterprise-grade software to a diverse range of industries, including automotive, telecom, banking, healthcare, manufacturing, retail, and technology. With a strong focus on Enterprise Linux, Kubernetes Management, and Edge solutions, SUSE supports mission-critical workloads for over 60% of the Fortune 500 companies. The company emphasizes collaboration with partners and communities to empower customers to innovate across various environments, from data centers to the cloud and edge. SUSE offers consulting, blended services, and training and certification, primarily generating revenue from subscriptions. Headquartered in Nuremberg, Germany, SUSE employs nearly 2,000 people globally and derives a significant portion of its revenue from North America.
MediFox
Debt Financing in 2018
MediFox GmbH, founded in 1994 and headquartered in Hildesheim, Niedersachsen, Germany, specializes in developing software solutions for ambulatory nursing care service providers and nursing care homes. The company offers enterprise system software designed to support outpatient care services, inpatient facilities, and therapeutic practices. MediFox's software encompasses essential services such as resource and route planning, care and support documentation, management information systems, and administration services, including billing and factoring. By providing these tools, MediFox enables care providers to enhance their organizational structure and streamline their processes in response to evolving industry needs.
BBS Automation
Private Equity Round in 2018
BBS Automation GmbH is a provider of automation solutions and engineering services, specializing in the design, development, manufacturing, and installation of automated assembly and testing systems. The company serves a diverse range of industries, including automotive, aerospace, life sciences, consumer goods, electronic devices, energy storage, and renewable energy. BBS Automation also offers leak detection, build-to-print services, and winding technology solutions, along with training and after-sales support. With nearly 550 employees, the company operates production sites in Germany, China, Malaysia, and the United States, partnering with prominent global clients. Founded in 1891 and headquartered in Garching bei München, Germany, BBS Automation is committed to delivering flexible and high-quality automation solutions for complex manufacturing and testing processes.
Simplify Medical
Series B in 2018
Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.
Studienkreis
Venture Round in 2017
Studienkreis is one of Germany's largest providers of professional tutoring services, operating nearly 1,000 tuition schools nationwide since its establishment in 1974. The company specializes in providing offline and digital tutoring aimed at primary and secondary school students, offering support across all major subjects through its proprietary teaching materials and scientifically backed learning methodologies. Studienkreis focuses on helping children and adolescents enhance their academic performance and achieve consistently good grades. In addition to addressing specific academic queries, the company emphasizes fostering independent learning skills and a sense of responsibility in students, thereby improving their overall confidence in their educational journey.
Xeltis
Series C in 2017
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
Dentconnect
Acquisition in 2017
DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.
Atricom and Le Büro
Private Equity Round in 2017
Two modern and strategically located office buildings in suburban Frankfurt.
Simplify Medical
Series B in 2017
Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.
Open Systems
Acquisition in 2017
Open Systems AG, established in 1990 and headquartered in Zurich, Switzerland, specializes in providing comprehensive managed security services to global enterprises, NGOs, and institutions. The company offers a range of services, including network security, application delivery, identity management, and global connectivity, ensuring secure and reliable IT networks and business-critical applications. Open Systems' offerings encompass distributed and enterprise firewall services, WAN encryption, network security monitoring, and incident response, among others. Serving diverse sectors such as finance, healthcare, and government, the company aims to deliver effective security solutions tailored to clients' unique needs.
Cardior Pharmaceuticals
Series A in 2017
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.
GETEC
Acquisition in 2017
GETEC is a group of energy service providers operating across Germany and Europe, employing nearly 1,400 individuals. The company specializes in a comprehensive range of energy services within the liberalized energy market, focusing on areas such as energy efficiency, system design, and zero emissions. GETEC aims to guide clients through the complexities of the energy landscape by developing customized and sustainable solutions that prioritize efficiency, economic viability, and resource conservation. Its approach is centered on creating added value for clients, helping them to improve their carbon footprint while considering the long-term implications for future generations.
GlobalConnect
Acquisition in 2016
GlobalConnect is a prominent alternative provider of fiber network, data center, and managed hosting services in Northern Europe, primarily focusing on Denmark and Germany. Established in 1998 by Niels Zibrandtsen, the company operates a 12,500 km optical fiber network and manages approximately 13,000 square meters of data center space. GlobalConnect offers a range of services including bandwidth connectivity, colocation, and cloud infrastructure, catering to both enterprises and consumers. With a workforce of over 200 employees, the company is dedicated to delivering fast and reliable networking solutions, enhancing connectivity and technological capabilities for its clients across Sweden, Norway, Denmark, Finland, and Northern Germany.
GETEC
Acquisition in 2016
GETEC is a group of energy service providers operating across Germany and Europe, employing nearly 1,400 individuals. The company specializes in a comprehensive range of energy services within the liberalized energy market, focusing on areas such as energy efficiency, system design, and zero emissions. GETEC aims to guide clients through the complexities of the energy landscape by developing customized and sustainable solutions that prioritize efficiency, economic viability, and resource conservation. Its approach is centered on creating added value for clients, helping them to improve their carbon footprint while considering the long-term implications for future generations.
CHEP
Acquisition in 2016
CHEP is a global provider of supply chain management solutions, specializing in the rental and maintenance of reusable containers, pallets, and other equipment. Its subsidiary, CHEP Aerospace Solutions, focuses on managing and repairing Unit Load Devices (ULDs), galley carts, and ground support equipment for the aviation industry. Headquartered in Zurich, Switzerland, CHEP Aerospace Solutions serves over 80 airlines worldwide, enabling them to concentrate on core operations while reducing costs and enhancing sustainability.
Onward
Series A in 2016
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
kfzteile24
Venture Round in 2016
kfzteile24 GmbH is a German retailer specializing in automotive spare parts and accessories, operating primarily online through its platforms www.kfzteile24.de and www.autoteile24.de. Founded in 2001 and headquartered in Berlin, the company has established itself as one of the largest online auto parts retailers in Germany, achieving significant sales growth over the years. In addition to its online presence, kfzteile24 operates three physical retail stores that are affiliated with repair shops, enhancing its service offerings. The company provides a wide range of automotive products, including exhaust systems, batteries, and braking systems, and features a vehicle selection tool that facilitates the quick identification of required parts. Customers also benefit from in-house support from automotive experts who assist in finding suitable replacement parts at competitive prices.
Kuoni Destination Management
Acquisition in 2016
Kuoni Reisen Holding AG is a Switzerland-based company that serves the travel industry and government sectors through three primary business activities. It operates Global Travel Distribution (GTD), which supplies hotel accommodations and destination services to travel companies and agents. The company also offers Global Travel Services (GTS), which coordinates comprehensive destination management services, including accommodation, transportation, tours, and event management. Additionally, Kuoni provides Visa Facilitation Services (VFS) through numerous application centers worldwide, assisting with visa outsourcing. The company further enhances its portfolio with Kuoni Destination Management, specializing in event development, budgeting, and creative direction, as well as providing entertainment and AV technology solutions for various events. This diverse range of services underscores Kuoni's commitment to delivering innovative and comprehensive travel and event solutions.
Apleona
Acquisition in 2016
Apleona is a professional services firm based in Neu Isenburg, Germany, established in 2016. The company specializes in comprehensive real estate services within the DACH region (Germany, Austria, and Switzerland). Its offerings span facility management, building technology, interior fittings, and real-estate management, including commercial services like letting, leasing, and marketing. Apleona caters to a diverse client base comprising banks, investment funds, industrial companies, and insurance firms, aiming to enhance their operational performance across multiple locations.
Xeltis
Series B in 2015
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
Sequana Medical
Series C in 2015
Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.
kfzteile24
Acquisition in 2015
kfzteile24 GmbH is a German retailer specializing in automotive spare parts and accessories, operating primarily online through its platforms www.kfzteile24.de and www.autoteile24.de. Founded in 2001 and headquartered in Berlin, the company has established itself as one of the largest online auto parts retailers in Germany, achieving significant sales growth over the years. In addition to its online presence, kfzteile24 operates three physical retail stores that are affiliated with repair shops, enhancing its service offerings. The company provides a wide range of automotive products, including exhaust systems, batteries, and braking systems, and features a vehicle selection tool that facilitates the quick identification of required parts. Customers also benefit from in-house support from automotive experts who assist in finding suitable replacement parts at competitive prices.
Kuros Biosciences
Post in 2015
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.
HusCompagniet
Acquisition in 2015
HusCompagniet A/S is a prominent house builder primarily operating in Denmark, with expanding activities in Sweden and Germany. The company specializes in the design, sale, and delivery of customizable single-family detached houses, which are largely constructed on-site on land owned by customers. Additionally, HusCompagniet offers semi-detached houses to both consumers and professional investors, and produces prefabricated wood-framed houses under the VårgårdaHus brand in Sweden. Headquartered in Horsens, Denmark, the company has established a strong market presence, being three times larger than its nearest competitor in Denmark. Since its incorporation in 2015, HusCompagniet has achieved significant revenue growth and has been recognized as House Builder of the Year in Denmark for three consecutive years, employing around 230 people and delivering over 1,000 houses annually across its markets.
Neuravi
Series B in 2015
Neuravi, established in 2009 and based in Galway, Ireland, specializes in the design and development of clot retrieval devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries, collaborating with international researchers and clinicians to advance understanding and treatment of ischemic stroke. As of 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.
Cardiac Dimensions
Series A in 2015
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
Xeltis
Series B in 2014
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.
Curetis
Series B in 2014
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
Evidensia Djursjukvård
Acquisition in 2014
Evidensia Djursjukvård AB is a veterinary clinic chain headquartered in Stockholm, Sweden, operating over 180 clinics and hospitals across Sweden, Norway, Denmark, Finland, Germany, Holland, and Switzerland. The company provides a comprehensive range of animal care services, including veterinary care, food, medicine, and supplies for various pets, such as dogs, cats, small animals, exotic animals, and horses. Through its extensive network, Evidensia aims to deliver quality veterinary services to pet owners in multiple countries.
Charleston Holding
Acquisition in 2014
Charleston Holding is an operator of nursing homes and residential care facilities in Germany, focused on serving physically and mentally impaired residents. The company adopts a buy-and-build strategy within the nursing home market, aiming to enhance its portfolio through acquisitions. Charleston provides a range of services, including nursing care, preventative care, and intensive care, along with assisted living and daycare options. By offering these services, Charleston Holding seeks to improve the quality of life for its residents and support their well-being into old age.
Swiss Smile
Private Equity Round in 2013
Swiss Smile is a medical company specializing in dental services, founded in 2003 by Haleh Bronner and Golnar Signer. The company offers a comprehensive range of dental care, including prevention, preservation, tooth removal and replacement, teeth straightening, beautification, and hygiene treatments. In addition to these services, Swiss Smile provides dentistry classes in schools, promoting oral health education. The company operates clinics in various locations across Switzerland, including Zurich, Baden, Bulach, St. Moritz, Suhr, and Winterthur, serving individuals with competitive pricing for treatments such as teeth whitening and cleaning.
EEW Energy from Waste
Acquisition in 2013
EEW Energy from Waste GmbH is a German company specializing in waste incineration and the generation of energy from waste. Founded in 1873 and based in Helmstedt, it operates 37 modern plants across 19 locations, efficiently recycling approximately five million tons of waste annually. The company produces climate-neutral electricity, process steam, and district heating, serving around 500,000 households. EEW Energy from Waste is committed to environmentally friendly waste disposal and resource conservation, utilizing by-products such as slag for road construction. With a workforce of 1,300 employees, the company continually strives to enhance its processes and efficiency through research collaborations with universities. EEW Energy from Waste emphasizes safe waste disposal for local councils and businesses while providing innovative energy solutions designed for the future.
Internetstores
Venture Round in 2012
Internetstores GmbH is a German-based company, established in 2003, that operates both online and physical retail stores specializing in bicycles and outdoor products. Its offerings include a wide range of bikes, sportswear, accessories, and outdoor adventure gear, catering to both recreational and hobbyist customers. With a presence in Germany, Sweden, and France, the company maintains retail stores in these countries and has additional offices in Esslingen, Stuttgart, Berlin, Lyon, and Stockholm. As a subsidiary of Signa Retail GmbH, internetstores operates as a multi-store e-commerce platform, serving customers across Europe.
Vivoryon Therapeutics
Venture Round in 2012
Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.
Sapiens Steering Brain Stimulation
Series A in 2011
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.
United Digital Group
Acquisition in 2011
United Digital Group is a digital communication and marketing agency based in Hamburg, Germany, founded by Michael Riese in 1999. The company focuses on providing businesses with digitalization strategies and branding solutions, primarily serving clients in the finance, cosmetics, and jewelry sectors. Its services include consulting, analytics, and redesigning business applications, as well as brand management and e-learning solutions. Additionally, United Digital Group specializes in technology strategy, strategic planning, content production, affiliate marketing, dashboard development, channel planning, data analytics, and project management.
AcadeMedia
Acquisition in 2010
AcadeMedia is the largest independent education provider in Northern Europe, offering a comprehensive range of educational services from pre-schools to adult education. The company operates approximately 550 units primarily in Sweden, Norway, and Germany. Its educational segments include preschools, compulsory schools, upper secondary schools, and adult education, with the upper secondary school segment generating the highest revenue. AcadeMedia's upper secondary school brands include Praktiska, Drottning Blanka, NTI, LBS, ProCivitas, and Rytmus. The majority of the company's revenue is derived from its operations in Sweden, reflecting its strong presence in the region's education sector.
Curetis
Series A in 2009
Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.
Vivoryon Therapeutics
Series B in 2009
Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.
Sausalitos Holding
Private Equity Round in 2008
Sausalitos Holding GmbH, established in 1994 and headquartered in Munich, Germany, operates a chain of casual dining pubs, offering a diverse menu of food and drinks. It specializes in Californian-Mexican cuisine, serving dishes and cocktails inspired by authentic Mexican recipes and current culinary trends. The company is recognized as one of Germany's leading leisure restaurant chains, providing dining options for breakfast, lunch, and dinner.
PharmaZell
Debt Financing in 2007
PharmaZell GmbH is a German company that specializes in the development and production of generic active pharmaceutical ingredients (APIs), controlled substances, and amino acids. Founded in 1947 and headquartered in Raubling, Germany, it operates production facilities in Switzerland, Italy, and India, along with a sales branch in the United States. The company provides services for formulation development and regulatory documentation, catering to both originator and generic pharmaceutical sectors. With a focus on delivering tailored solutions through a flexible technology platform, PharmaZell aims to address the specific needs of its clients across the global pharmaceutical industry. The company is committed to ethical practices and prioritizes environmental responsibility, ensuring that it maintains strong relationships with its business partners and employees.
Okairos
Series A in 2007
Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.
Scandic Hotels
Acquisition in 2007
Scandic Hotels Group is a Sweden-based hotel operator with a portfolio of over 200 hotels across approximately 120 destinations, primarily in the Nordic region. The company caters to both corporate and leisure travelers, with a significant portion of its revenue generated from business travel, room services, restaurants, and conferences. Scandic Hotels operates in several countries including Sweden, Finland, Denmark, Norway, Belgium, Poland, and Germany, with Sweden serving as the largest market. This extensive network enables the company to offer a diverse range of accommodations and services tailored to meet the needs of its guests.
CBR
Acquisition in 2007
CBR is a fashion company based in Isernhagen, Germany, specializing in women's apparel. The company produces twelve collections annually for each of its labels, enabling quick turnover and responsiveness to market demands. CBR operates both retail and outlet stores, as well as an online platform, to reach a broad customer base. Through its diverse range of fashionable clothing, CBR aims to cater to the evolving preferences of women consumers while maintaining a strong presence in the competitive fashion industry.
4-Antibody
Series A in 2007
4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology platform to generate therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its technology to pharmaceutical partners, 4-Antibody AG is actively developing a pipeline of preclinical checkpoint antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.
Pfaff Beteiligungs GmbH
Acquisition in 2006
Pfaff-silberblau's lifting and material handling business includes wire rope winches, chain hoists, rack and pinion jacks and hand pallet trucks. Its actuator business designs, develops, manufactures and markets components for lifting and motion control, including worm gear screw jacks, linear motion precision screws and quick lifting screw jacks. Based in Kissing, Germany, Pfaff-silberblau employs over 300 people and is represented worldwide through six international subsidiaries as well as numerous regional representatives.
DNage
Series A in 2005
DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).
Metall Technologie Holding
Debt Financing in 2005
Metall Technologie Holding is a German manufacturer specializing in heat treatment industrial furnaces. The company produces a range of furnaces including vacuum, continuous, atmospheric, and protective gas furnaces, catering to diverse sectors such as aeronautics, automotive, medical, and steel manufacturing. Their furnaces are utilized for various heat treatment processes, including gas and oil quenching, brazing of metals, sintering, tempering, annealing, and other specialized treatments like low-pressure carburizing, nitriding, and cryogenic treatment. Metall Technologie Holding serves a global clientele that includes heat treatment contractors and equipment manufacturers, providing advanced solutions for industrial heating applications.
Sportfive (Active Sports Marketing)
Debt Financing in 2004
SPORTFIVE is an international sports marketing agency, owned by the French media group Lagardère Unlimited. The largest agency in the group’s dedicated sports and entertainment division (which includes fellow sports marketing agencies World Sport Group and IEC in Sports), SPORTFIVE employs around 500 people in offices spread across Europe and Asia. The agency offers more than 25 years of industry experience and prides itself on providing expertise and innovation across the full spectrum of sports marketing services. SPORTFIVE remains the leading sports agency in Germany, managing the marketing rights for a large number of top tier professional football clubs, in addition to selected rights for handball, winter sports and motorsports. The agency also enjoys an established reputation in France, working closely with clubs, federations and events across a variety of sports, and in Africa, where SPORTFIVE is the exclusive marketing and media agent of the Confédération Africaine de Football (CAF).
4-Antibody
Seed Round in 2004
4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology platform to generate therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its technology to pharmaceutical partners, 4-Antibody AG is actively developing a pipeline of preclinical checkpoint antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.
Nederman Holding
Acquisition in 1999
Nederman Holding AB is an industrial equipment manufacturer focused on developing, producing, and marketing solutions to extract and manage hazardous substances such as fumes. The company operates through four main segments: Extraction & Filtration Technology, Process Technology, Duct & Filter Technology, and Monitoring & Control Technology. Its products aim to improve air quality, enhance sustainability, and ensure compliance with emissions regulations in industrial settings. Nederman serves a global market, with significant operations in regions such as Sweden, Germany, the UK, the US, and parts of Asia. The majority of its revenue is derived from the Extraction & Filtration Technology segment, reflecting its commitment to reducing the harmful effects of industrial processes and protecting both people and the environment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.